BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 31018139)

  • 1. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
    Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
    Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.
    Fujiwara H; Takahara N; Tateishi K; Tanaka M; Kanai S; Kato H; Nakatsuka T; Yamamoto K; Kogure H; Arita J; Nakai Y; Kasuga M; Ushiku T; Hasegawa K; Koike K
    Surg Oncol; 2020 Dec; 35():484-490. PubMed ID: 33126085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs.
    Harada K; Sato Y; Ikeda H; Maylee H; Igarashi S; Okamura A; Masuda S; Nakanuma Y
    Virchows Arch; 2012 Mar; 460(3):281-9. PubMed ID: 22358181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
    Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
    Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
    Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
    Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterisation of six human biliary tract cancer cell lines.
    Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
    Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiological trends of biliary tract cancers in the United States of America.
    Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J
    BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
    Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
    Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
    Lamarca A; Barriuso J; McNamara MG; Valle JW
    J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
    Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
    Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to move to targeted drugs in biliary tract cancer?
    Louvet C; Tournigand C
    Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract]   [Full Text] [Related]  

  • 18. Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.
    Carotenuto P; Hedayat S; Fassan M; Cardinale V; Lampis A; Guzzardo V; Vicentini C; Scarpa A; Cascione L; Costantini D; Carpino G; Alvaro D; Ghidini M; Trevisani F; Te Poele R; Salati M; Ventura S; Vlachogiannis G; Hahne JC; Boulter L; Forbes SJ; Guest RV; Cillo U; Said-Huntingford I; Begum R; Smyth E; Michalarea V; Cunningham D; Rimassa L; Santoro A; Roncalli M; Kirkin V; Clarke P; Workman P; Valeri N; Braconi C
    Hepatology; 2020 Sep; 72(3):982-996. PubMed ID: 31879968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cancer After Surgical Resection.
    Utsumi M; Kitada K; Tokunaga N; Yoshida Y; Narusaka T; Hamano R; Miyasou H; Tsunemitsu Y; Otsuka S; Inagaki M
    Anticancer Res; 2021 Apr; 41(4):2147-2155. PubMed ID: 33813426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.